Vaccine Safety Registry
Meningococcal Vaccine Safety
Professional safety data on MenACWY and MenB vaccines. Clinical trial outcomes, manufacturer packages (Menactra, Menveo, Bexsero), and long-term surveillance.
Translate this vaccine safety monograph into your preferred language:
Clinical Overview
Professional summary
Meningococcal disease is a severe bacterial pathology capable of inducing rapid clinical decline through meningitis (neural lining infection) and septicemia (acute bloodstream infection).
Despite contemporary antibiotic interventions, the disease maintains a 10-15% mortality rate. Up to 20% of survivors present with permanent sequelae, including cognitive impairment, renal damage, hearing loss, or limb amputations.
Vaccine Formulations
Module specifics & formulations
Formulation Node
MenACWY: Serogroups A, C, W, Y
Registry data
- Menveo - GSK - 2 months to 55 years.
- MenQuadfi - Sanofi - 2 years +.
- Menactra - Sanofi - 9 months to 55 years.
Formulation Node
MenB: Serogroup B Protocol
Protocol
- Bexsero - GSK - 2-dose series.
- Trumenba - Pfizer - 2 or 3-dose series.
Clinical Triage
Eligibility & contraindications
MenACWY Protocol
- Preteen initiation (11-12 years)
- Teen booster (16 years)
- First-year collegiate residents
MenB Protocol
- Adolescents (16-23 years)
- Preferred window (16-18 years)
- Complement deficiency cohorts
Absolute & Relative Contraindications
- Hypersensitivity to previous meningococcal dose
- Acute moderate-to-severe illness state
- Shared decision-making for specific medical conditions
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized erythema
- Induration (Hardness)
- Injection site pain
Systemic Profile
- Generalized fatigue
- Cephalalgia (Headache)
- Myalgia / arthralgia
- GI distress (Nausea)
Surveillance Analytics
Post-market surveillance metrics
2026
Registry Cycle
Millions
Doses Monitored
High
Safety Confidence
Institutional Surveillance
Post-market surveillance through VAERS and FDA systems has identified no unexpected safety concerns. Meningococcal registry modules maintain an exemplary clinical risk-to-benefit profile.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Authoritative References & Clinical Citations
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
MMWR Recommendations and Reports, 69(9):1-41
- 2WHO2024Meningococcal vaccines: WHO position paper — November 2011
Weekly Epidemiological Record, 86(47):521-540
- 3FDA2024MENQUADFI, MENACTRA, BEXSERO, and PENBRAYA Prescribing Information & Safety Profile
U.S. Food and Drug Administration CBER
Authored by Dr. Simran Kohli and clinically reviewed by Dr. Vikram Patel, in alignment with HCP Connect Clinical Reviewers & Authors Directory. Content verified against 2026 CDC ACIP and WHO safety protocols.
Content Licensing: Available for non-commercial clinical, academic, and educational reuse under CC BY-NC-ND 4.0.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.